Go to
current issue
-
What is adequate preoxygenation? – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Shane George, Tara WilliamsNo Abstract
-
What is adequate preoxygenation? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Nirvik Pal, Bryant W TranNo Abstract
-
Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-30
Alexander Supady, Jan Bělohlávek, Alain Combes, Alice Hutin, Roberto Lorusso, Graeme MacLaren, Ingrid Magnet, Marcel van de Poll, Susanna Price, Dawid L Staudacher, Fabio Silvio Taccone, Demetri Yannopoulos, Daniel BrodieWhen conventional cardiopulmonary resuscitation (CCPR) cannot restore spontaneous circulation, the initiation of venoarterial extracorporeal membrane oxygenation during refractory cardiac arrest—known as extracorporeal CPR (ECPR)—might restore circulation and adequate tissue oxygenation. ECPR could substantially improve survival with favourable functional recovery. However, the complexity and time-sensitive
-
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-28
Job F M van Boven, Fernando de Mora, Giorgio W Canonica, Peter G M Mol, Arnold G VultoNo Abstract
-
Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-28
Wolfgang Merkt, Manuel Röhrich, Eleni Mavriopoulou, Ayla Nadja Stütz, Jörg H W Distler, Anita Schmitt, Markus Polke, Claus Peter Heußel, Michael Schmitt, Hanns-Martin LorenzSection snippets ContributorsWM and H-ML oversaw the project; MR and EM were involved with FAPI-PET/CT, including graphs; CPH was involved with CT-imaging, including graphs; WM, H-ML, AS, JHWD, and MP were responsible for clinical data interpretation; WM, MS, AS, H-ML, and MP cared for the patient; WM was responsible for data handling; WM and ANS wrote the manuscript; and all authors critically reviewed
-
Impact of Myanmar's earthquake on respiratory health Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-23
Sanjeet BagcchiNo Abstract
-
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-20
Stefanie Deinhardt-Emmer, Benjamin G Chousterman, Joerg C Schefold, Stefanie B Flohé, Tomasz Skirecki, Matthijs Kox, Martin S Winkler, Andrea Cossarizza, W Joost Wiersinga, Tom van der Poll, Markus A Weigand, Sara Cajander, Evangelos J Giamarellos-Bourboulis, Gunnar Lachmann, Massimo Girardis, Brendon P Scicluna, Ricard Ferrer, Didier Payen, Sebastian Weis, Antoni Torres, Hjalmar R BoumaSepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression
-
Everything is Tuberculosis | Everything is Tuberculosis John Green Ebury Press pp 208 ISBN 9781529961423 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-19
Talha BurkiNo Abstract
-
Innovative models of lung function across the lifespan Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-15
Sanja StanojevicNo Abstract
-
General population-based lung function trajectories over the life course: an accelerated cohort study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-15
Judith Garcia-Aymerich, Martí de las Heras, Anne-Elie Carsin, Simone Accordini, Alvar Agustí, Dinh Bui, Shyamali C Dharmage, James W Dodd, Ikenna Eze, Ulrike Gehring, Thorarinn Gislason, Raquel Granell, Medea Imboden, Carmen Íñiguez, Ayoung Jeong, Sarah Koch, Gerard H Koppelman, Bénédicte Leynaert, Erik Melén, Jennifer Perret, Rosa FanerBackgroundLung function is a key determinant of health, but current knowledge on lung function growth and decline over the life course is based on fragmented, potentially biased data. We aimed to empirically derive general population-based life course lung function trajectories, and to identify breakpoints and plateaus. MethodsWe created an accelerated cohort by pooling data from eight general population-based
-
Guidelines without borders: the case for JAK inhibitors as the first-line immunomodulator COVID-19 treatment Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-13
Daniel A Sweeney, Andre C KalilNo Abstract
-
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-13
Alain Amstutz PhD, Stefan Schandelmaier PhD, Hannah Ewald PhD, Benjamin Speich PhD, Johannes M Schwenke MSc, Christof M Schönenberger MD, Stephan Schobinger MD, Prof Thomas Agoritsas PhD, Kay M Tomashek MD, Seema Nayak MD, Mat Makowski PhD, Alejandro Morales-Ortega PhD, David Bernal-Bello PhD, Giovanni Pomponio MD, Alessia Ferrarini MD, Monireh Ghazaeian PharmD, Frances Hall PhD, Simon Bond PhD, MaríaEvidence from randomised clinical trials (RCTs) of Janus kinase (JAK) inhibitors—compared with usual care or placebo—in adults treated in hospital for COVID-19 is conflicting. We aimed to evaluate the benefits and harms of JAK inhibitors compared with placebo or usual care and whether treatment effects differed between prespecified participant subgroups.
-
Occupational respiratory harms: preventable, not inevitable Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-09
The Lancet Respiratory MedicineNo Abstract
-
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-08
Timothy E Weir, Helen James, Emily Carreiro, Margaret S HerridgeNo Abstract
-
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-05
Antoine Kimmoun, Connor O'Brien, Vanessa Blumer, Florian A Wenzl, Janine Pöss, Uwe Zeymer, Jacob E Møller, Nadia Aissaoui, Shashank S Sinha, Alain Combes, Naoki Sato, Alessandro Sionis, Sabri Soussi, Susanna Price, Rhonda E Monroe, Rebecca Mathew, Alexandre MebazaaDespite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have shown that increasing survival rates in cardiogenic shock is challenging. Even the most successful trials show 5–15% reductions in mortality, and gains have been restricted to acute myocardial infarction cardiogenic shock, representing approximately 5% of the population with
-
The rising threat of predatory journals and paper mills in respiratory medicine and research Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-02
Joan B Soriano, Alberto Ruano-RavinaNo Abstract
-
Time T—to understand treatment response Lancet Respir. Med. (IF 38.7) Pub Date : 2025-05-01
Iwein Gyselinck, Helene Huts, Maarten De Vos, Wim JanssensNo Abstract
-
Tracing the threads of air pollution Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-29
Peter RanscombeNo Abstract
-
Defining and subphenotyping ARDS: insights from an international Delphi expert panel Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-29
Prashant Nasa, Lieuwe D Bos, Elisa Estenssoro, Frank M P van Haren, Ary Serpa Neto, Patricia R M Rocco, Arthur S Slutsky, Marcus J SchultzAlthough the definition of acute respiratory distress syndrome (ARDS) has undergone numerous revisions aimed at enhancing its diagnostic accuracy and clinical practicality, the usefulness and precision of these definitions remain matters of ongoing discussion. In this Position Paper, we report on a Delphi study to reach a consensus on the conceptual model of ARDS, specifically identifying its defining
-
C-reactive protein-guided treatment in pneumonia: charting a personalised approach Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-29
Shota Yamamoto, Ryosuke Imai, Takayuki NiitsuNo Abstract
-
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-29
Jim M Smit, Jesse H Krijthe, Gianfranco U Meduri, Pierre-François Dequin, Harin Karunajeewa, Antoni Torres, Marcel J T Reinders, Henrik Endeman, Philip A Van Der ZeeNo Abstract
-
Common and rare variants and survival in idiopathic pulmonary fibrosis Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-28
Effrosyni D Manali, Caroline Kannengiesser, Spyros A PapirisNo Abstract
-
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-28
Aitana Alonso-González PhD, David Jáspez MSc, José M Lorenzo-Salazar MSc, Shwu-Fan Ma PhD, Emma Strickland BA, Prof Josyf Mychaleckyj PhD, John S Kim MD, Yong Huang PhD, Ayodeji Adegunsoye MD, Justin M Oldham MD, Iain Stewart PhD, Prof Philip L Molyneaux PhD, Prof Toby M Maher PhD, Prof Louise V Wain PhD, Richard J Allen PhD, Prof R Gisli Jenkins PhD, Jonathan A Kropski MD, Brian Yaspan PhD, TimothyRare pathogenic variants in telomere-related genes are associated with poorer clinical outcomes in idiopathic pulmonary fibrosis (IPF). We aimed to assess whether rare qualifying variants in monogenic adult-onset pulmonary fibrosis genes are associated with IPF survival. Using polygenic risk scores (PRS), we also evaluated the influence of common IPF risk variants in patients carrying the qualifying
-
Air-Borne: The Hidden History of the Life we Breathe | Air-Borne: The Hidden History of the Life we Breathe Carl Zimmer Penguin Group. pp 496 ISBN: 9780593473597 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-23
Vijay Shankar BalakrishnanNo Abstract
-
US judge halts Trump's clawback of public health funds Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-24
Bryant FurlowNo Abstract
-
Health effects from climate-driven events: lessons learnt Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-16
The Lancet Respiratory MedicineNo Abstract
-
Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-15
Elizabeth S Munroe MD, Alexandra Spicer MS, Andrea Castellvi-Font MD, Ann Zalucky MD, Jose Dianti MD, Emma Graham Linck MS, Victor Talisa PhD, Martin Urner MD, Prof Derek C Angus MD, Elias Baedorf-Kassis MD, Bryan Blette PhD, Lieuwe D Bos MD, Kevin G Buell MBBS, Jonathan D Casey MD, Prof Carolyn S Calfee MD, Lorenzo Del Sorbo MD, Prof Elisa Estenssoro, Niall D Ferguson MD, Rachel Giblon MS, AndersClinicians aim to provide treatments that will result in the best outcome for each patient. Ideally, treatment decisions are based on evidence from randomised clinical trials. Randomised trials conventionally report an aggregated difference in outcomes between patients in each group, known as an average treatment effect. However, the actual effect of treatment on outcomes (treatment response) can vary
-
Correction to Lancet Respir Med 2025; 13: 35–46 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14
Zein JG, Zounemat-Kermani N, Adcock IM, et al. Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts. Lancet Respir Med 2025; 13: 35–46—In this Article, the spelling of author Nazanin Zounemat-Kermani's name was incorrect. The Acknowledgments section has also been updated to
-
The big five vexing questions of respiratory syncytial virus immunisation Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14
Farina Leonie Shaaban, Louis J BontNo Abstract
-
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14
Michael G Ison MD, Prof Alberto Papi MD, Prof Eugene Athan MD, Robert G Feldman MD, Prof Joanne M Langley MD, Prof Dong-Gun Lee MD, Isabel Leroux-Roels MD, Prof Federico Martinon-Torres MD, Prof Tino F Schwarz MD, Prof Richard N van Zyl-Smit MD, Susanna Cuadripani MD, Quentin Deraedt PhD, Nancy Dezutter PhD, Catherine Gerard PhD, Laurence Fissette MS, Stebin Xavier MS, Marie-Pierre David MS, AurélieDuration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed to evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults.
-
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-12
Aoife Leonard, Brian O’Brien, Ian Conrick-Martin, Karen Healy, Alan GaffneyNo Abstract
-
Microplastics: an underestimated and underregulated crisis Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08
Vijay Shankar BalakrishnanNo Abstract
-
Climate change fuels deadly dust storms worldwide Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08
Bryant FurlowNo Abstract
-
Inflammatory risks and asthma attacks: what comes next? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08
Mona Al-Ahmad, Asmaa AliNo Abstract
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08
Fleur L Meulmeester MSc, Samuel Mailhot-Larouche MD, Carlos Celis-Preciado MD, Samuel Lemaire-Paquette MSc, Sanjay Ramakrishnan PhD, Prof Michael E Wechsler MD, Prof Guy Brusselle MD, Prof Jonathan Corren MD, Jo Hardy PhD, Sarah E Diver PhD, Prof Christopher E Brightling FMedSci, Prof Mario Castro MD, Prof Nicola A Hanania MD, Prof David J Jackson PhD, Prof Neil Martin MD, Annette Laugerud MD, EmilioClinical risk factors for severe asthma attacks have been identified, but their incremental prognostic values are unclear. Additionally, the incremental contribution of type 2 inflammation, a common, treatable process, is undetermined. We aimed to quantify the prognostic value of baseline characteristics and type 2 inflammatory biomarkers, specifically blood eosinophil count and fractional exhaled
-
Pneumonia: a neglected global threat Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01
No Abstract
-
The weight of air: a Commission on palliative care integration in serious respiratory illness Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01
William E Rosa, Afsan Bhadelia, Gemma Bowsher, Mark Dransfield, Anand S Iyer, Felicia Marie Knaul, Kathleen Lindell, Matthew Maddocks, Christian Ntizimira, Obianuju Ozoh, Pedro E Pérez-Cruz, Lukas Radbruch, Smriti Rana, Anne-Marie Russell, Mac Skelton, Natasha Smallwood, Samuel Byiringiro, Jeffersson Santos, Donald R SullivanNo Abstract
-
Correction to Lancet Respir Med 2025; 13: 318–26 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01
Norberg SM, Valdez J, Napier S, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. Lancet Respir Med 2025; 13: 318–26—In this Article, some of the appendix page numbers in the main text and an abbreviation in the tables have been updated, and missing or switched data for patients 8, 10, 11, 12, 13, and 27 in figure 2 have been corrected
-
Targeting neutrophil serine proteases in bronchiectasis—where are we now? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-25
Oleksandr MazulovNo Abstract
-
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-25
Prof Nan-Shan Zhong BMed, Prof Rong Qiu MMed, Prof Jie Cao MMed, Prof Yan-Ming Huang MMed, Prof Hua Zhou MD, Prof Xing-Xiang Xu MD, Prof Jin-Fu Xu MD, Prof Huan Ye BMed, Prof Zhi-Ren Yang MD, Prof Ling-Yun Gao MD, Prof Yao Shen MD, Prof Zu-Ke Xiao BMed, Prof Shi-Guang Xie MD, Prof Dian-Jie Lin MD, Prof Li Zhao MD, Prof Hao Xiong BMed, Prof Xian-Ming Zhang MD, Fang-Qiong Li MMed, Prof Wei-Jie Guan PhDAirway neutrophil inflammation with excessive neutrophil serine proteases is implicated in frequent exacerbations of bronchiectasis. HSK31858 is a novel reversible inhibitor of DPP-1. We aimed to assess the efficacy and safety of HSK31858 in decreasing the frequency of bronchiectasis exacerbations among adults with bronchiectasis.
-
Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
GBD 2021 Asthma and Allergic Diseases Collaborators, Jiyeon Oh, Soeun Kim, Min Seo Kim, Yohannes Habtegiorgis Abate, Samar Abd ElHafeez, Atef Abdelkader, Parsa Abdi, Deldar Morad Abdulah, Richard Gyan Aboagye, Hassan Abolhassani, Dariush Abtahi, Hasan Abualruz, Eman Abu-Gharbieh, Salahdein Aburuz, Mesafint Molla Adane, Isaac Yeboah Addo, Olumide Thomas Adeleke, Bashir Aden, Qorinah Estiningtyas SakilahAsthma and atopic dermatitis are common allergic conditions that contribute to substantial health loss, economic burden, and pain across individuals of all ages worldwide. Therefore, as a component of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we present updated estimates of the prevalence, disability-adjusted life-years (DALYs), incidence, and deaths due to asthma
-
Predicting the future global burden of asthma and atopic dermatitis: identifying strategies for prevention Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
Erik Melén, Judith Garcia-AymerichNo Abstract
-
Addressing the growing TB disease burden in England Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
Kerry A Millington, Rebecca Nightingale, Naomi F Walker, Beate Ringwald, Daire Cantillon, Fatima Karmadwala, Tom WingfieldNo Abstract
-
Unveiling a hidden phenotype of early tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
Joanna Ehrlich, Clara Suñer, Gavin Churchyard, Frank Cobelens, Mark Hatherill, Simon C Mendelsohn, Kristin N Nelson, Tom Scriba, Grant Theron, Leonardo Martinez, Alberto L Garcia-BasteiroNo Abstract
-
End of USAID leaves enormous funding shortfall for TB Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
Talha BurkiNo Abstract
-
The importance of post-tuberculosis morbidity in high-income countries Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22
Ailva O’Reilly, Dominik Zenner, Pranabashis Haldar, Samara Barnes, Jamilah Meghji, Manish PareekNo Abstract
-
Transition of adolescents with asthma to adult care Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22
Priya VenkatesanNo Abstract
-
Post-tuberculosis lung disease: towards prevention, diagnosis, and care Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22
Jamilah Meghji PhD, Sara C Auld MD, Gregory P Bisson MD, Celso Khosa PhD, Refiloe Masekela PhD, Neelima Navuluri MD, Andrea Rachow MDThere is a growing body of data describing the high burden of respiratory sequelae seen among tuberculosis survivors, including children, adolescents, and adults. This group of sequelae are known as post-tuberculosis lung disease and include parenchymal damage, airway disease, and pulmonary vascular disease. It is thought that approximately half of pulmonary tuberculosis survivors have ongoing structural
-
Equitable, personalised medicine for tuberculosis: treating patients, not diseases Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22
Lorenzo Guglielmetti, Samiran Panda, Amanzhan Abubakirov, Naseem Salahuddin, Christophe Perrin, Carole D MitnickNo Abstract
-
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21
Tyler Pitre, Winnie Liu, Dena Zeraatkar, Jonathan D Casey, Joanna C Dionne, Kevin W Gibbs, Adit A Ginde, Natalie Needham-Nethercott, Todd W Rice, Matthew W Semler, Bram RochwergBackgroundPreoxygenation is a crucial preparatory step for intubation. Several strategies for preoxygenation exist, including facemask oxygen, high-flow nasal cannula (HFNC), and non-invasive positive pressure ventilation (NIPPV). However, the comparative efficacy of these strategies remains largely uncertain. We aimed to compare the efficacy and safety of HFNC, NIPPV, and facemask oxygen for preoxygenation
-
Preoxygenation for tracheal intubation in adults who are critically ill: time to abandon the facemask? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21
Sheila Nainan Myatra, Samir JaberNo Abstract
-
Nasal high-flow oxygen for apnoeic oxygenation during emergency endotracheal intubation of children Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21
Emma C Alexander, Padmanabhan RamnarayanNo Abstract
-
Effectiveness of nasal high-flow oxygen during apnoea on hypoxaemia and intubation success in paediatric emergency and ICU settings: a randomised, controlled, open-label trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21
Shane George PhD, Tara Williams MSN, Susan Humphreys MBBCH, Tiffany Atkins MBiostat, Prof David Tingay PhD, Ben Gelbart PhD, Trang Pham MEng, Prof Simon Craig PhD, Simon Erickson MBBS, Arjun Chavan MBBS, Katie Rasmussen MBBS, Anusha Ganeshalingham MBChB, Felix Oberender PhD, Subodh Ganu MD, Nitesh Singhal MD, Prof Kristen Gibbons PhD, Renate Le Marsney MPH, Juerg Burren MD, Prof Luregn J SchlapbachThe use of nasal high-flow (NHF) oxygen for apnoeic oxygenation during emergency paediatric intubation is not universally adopted. Although previous studies suggest potential benefits, it remains unclear whether NHF enhances the likelihood of achieving successful first-attempt intubation without oxygen desaturation in children. We aimed to investigate whether the provision of NHF oxygen during paediatric
-
The bidirectional complexity of multiple long-term conditions and post-COVID-19 condition Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18
Kamlesh Khunti, Rachael A Evans, Amitava Banerjee, Christina van der Feltz-CornelisNo Abstract
-
Positive airway pressure and all-cause and cardiovascular mortality in people with obstructive sleep apnoea Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18
Ye Zhang, Virend K Somers, Xiangdong TangNo Abstract
-
Positive airway pressure therapy and all‐cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18
Adam V Benjafield PhD, Prof Jean-Louis Pepin MD, Prof Peter A Cistulli MD, Alison Wimms PhD, Florent Lavergne MSc, Fatima H Sert Kuniyoshi PhD, Sibyl H Munson PhD, Brendan Schuler BS, Shrikar Reddy Badikol MSc, Kelly C Wolfe BS, Leslee Willes MPH, Colleen Kelly PhD, Tetyana Kendzerska MD, Dayna A Johnson PhD, Prof Raphael Heinzer MD, Prof Chi-Hang Lee MD, Prof Atul Malhotra MD, medXcloud GroupData regarding the effect of positive airway pressure (PAP) therapy for obstructive sleep apnoea (OSA) on all-cause mortality are inconsistent. We aimed to conduct a systematic review and meta-analysis to test the hypothesis that PAP therapy is associated with reduced all-cause and cardiovascular mortality in people with OSA.
-
Withdrawal of life sustaining therapies in patients with or without acute brain injury Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-17
Scott R DeBoer, Romergryko GeocadinNo Abstract
-
Decisions to withdraw or withhold life-sustaining therapies in patients with and without acute brain injury: a secondary analysis of two prospective cohort studies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-17
Shaurya Taran MD, Kuan Liu PhD, Victoria A McCredie MBChB, Oscar Penuelas MD, Prof Karen E A Burns MD, Fernando Frutos-Vivar MD, Prof Damon C Scales MD, Prof Niall D Ferguson MD, Jeffrey M Singh MD, Armaan K Malhotra MD, Neill K J Adhikari MDCMMany deaths in the intensive care unit (ICU) occur after a decision to withdraw or withhold life-sustaining therapies (WLSTs). We aimed to explore the differences in the incidence and timing of WLST between patients with and without acute brain injuries (ABIs).
-
An overview of influenza H5 vaccines Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-13
Jessica Taaffe, Shuyi Zhong, Shoshanna Goldin, Kate S Rawlings, Benjamin J Cowling, Wenqing ZhangNo Abstract
-
Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-12
Elena Kum, Wafa Hassan, Imran SatiaNo Abstract
更新日期：2025-04-28
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号